Results

1–10 of 290 results for Anti-VEGF

Progression of Geographic Atrophy in Patients Receiving Both Anti-VEGF and Pegcetacoplan Injections
Sean David Adrean, MD, FAAO, FASRS
Annual Meeting Talks
2025
Safety Profiles of Combined Anticomplement and Anti-VEGF Intravitreal Therapies for Age-Related MacularDegeneration From Real-World Data
Edward H. Wood, MD, FASRS
Annual Meeting Talks
2025
A Descriptive Analysis of Patients Who Received Pegcetacoplan and Anti-VEGF for the Treatment ofGeographic Atrophy and Neovascular AMD
Nimesh A. Patel, MD
Annual Meeting Talks
2025
Impact of PDS in Study Eyes vs Anti-VEGF Injections in Fellow Eyes in Pagoda Trial Patients With BilateralDiabetic Macular Edema (DME)
Jordan M. Graff, MD, FACS
Annual Meeting Talks
2025
Interim Results From the SPECTRA Phase 2a Clinical Trial Evaluating Intravitreal 4D-150 in Adults WithDiabetic Macular Edema
David RP Almeida, MD, MBA, PhD, DABO, FRCSC, FASRS
Annual Meeting Talks
2025
Early Insights From Real-World Use of Aflibercept 8 mg Among Eyes With Diabetic Macular Edema SwitchingFrom Other Anti-VEGF Agents
Michael Javaheri, MD
Annual Meeting Talks
2025
VERONA: End-of-Study Results From a Phase 2 Trial of EYP-1901 (Vorolanib Intravitreal Insert) vs Afliberceptfor Diabetic Macular Edema
Yasha S Modi, MD
Annual Meeting Talks
2025
Evaluating the Visual, Anatomic, and Treatment Effects of Switching from Higher-cost Anti-VEGF to Lower-cost Bevacizumab After Loss of Copay Assistance (Good Days) Funding in Neovascular Age-Related Macular Degeneration
Jesse J Jung, MD, FASRS
Updates from the Field
2026
Safety of Continuing Anti-VEGF Therapy Around the Time of Nonophthalmic Incisional Surgery: A Multisite Matched Cohort Study
Odette M. Houghton, MD
Updates from the Field
2026
Progression to Pars Plana Vitrectomy After Monotherapy With Panretinal Photocoagulation or Anti-VEGF injections in Proliferative Diabetic Retinopathy
Karen M Wai, MD
Annual Meeting Talks
2023